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Introduction
Patients with advanced or metastatic non-small cell lung cancer
(NSCLC) benefit from a platinum-containing doublet [1]. In addition, re-
cently developed monoclonal antibodies, such as cetuximab and beva-
cizumab, can be more beneficial in combination with chemotherapy for
a selected subset of these patients [2,3]. As a second-line or third-line ther-
apy, single agent docetaxel, pemetrexed and oral epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR TKI) improved the survival out-
come as well [4-7]. Even though the survival outcomes have much im-
proved during the last decade, most patients might have progressive dis-
ease (PDs) regardless of their responsiveness to previous chemotherapy
or molecular-targeted therapy. Therefore, in such cases, if they still have
a rather good performance status, we usually recommend that they par-
ticipate in clinical trials with a new drug or a combination of drugs.
S-1 (Jeil Pharmaceutical Co., Ltd., Seoul, Korea) is an oral anticancer
drug comprised of tegafur, 5-chloro-2,4-dihydroxipyridine, and potassium
oxonate [8]. Tegafur is a prodrug that generates 5-fluorouracil (5-FU) in
the blood via metabolism by liver enzymes, and 5-chloro-2,4-dihydrox-
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Purpose
This study was designed to evaluate the efficacy of a combination treatment of S-1 plus either
irinotecan or docetaxel for advanced/metastatic non-small cell lung cancer (NSCLC) patients
who have already failed 3 or more lines of treatment. 
Materials and Methods
This was a prospective single center phase II study. The eligible patients received S-1 40 mg/m2
twice a day orally on days 1 though 14 combined with irinotecan 150 mg/m2on D1 only or docetaxel
35 mg/m2on D1 and D8. The treatment was repeated every 3 weeks until disease progression,
unacceptable toxicity, or patient refusal. The choice between the two regimens was made at the
discretion of the treating physician.
Results
A total of 14 patients participated in the study. There were 3 patients with squamous cell carci-
noma, 9 with adenocarcinoma, and 2 with NSCLC, NOS. Eight of the patients were male. There
were 8 patients with an Eastern Cooperative Oncology Group (ECOG) of 1, and 6 patients with an
ECOG of 2. All the patients had already been treated with platinum-based chemotherapy and epi-
dermal growth factor receptor tyrosine kinase inhibitor therapy. Out of the 14 patients, 10 received
irinotecan and S-1 and the other 4 received docetaxel and S-1. Twelve patients had also received
pemetrexed. Disappointingly, there were no response from 2 patients with a stable disease, and
therefore, as per the protocol, we stopped the study early. With a median follow-up time of 49
months, the median survival time was 5.6 months (95% confidence interval, 4.3 to 6.9 months).
Conclusion
S-1 containing doublets did not show activity in this population as a salvage treatment and further
investigation cannot be recommended.
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ypyridine enhances the serum concentration of 5-FU by the competitive
inhibition of dihydropyrimidine dyhydrogenase, which is an enzyme re-
sponsible for 5-FU catabolism. Potassium oxonate is also a reversible
competitive inhibitor of oratate phosphoribosyl transferase, a phospho-
enzyme for 5-FU. The diarrhea induced by 5-FU administration is thought
to be attributable to the phosphorylation of 5-FU by enzyme in the gas-
trointestinal tissue, and after the oral administration of potassium oxonate,
the concentration of potassium in the gastrointestinal tissue is high enough
to inhibit the enzyme while the concentration of potassium in the blood
and tumor is reported to be either slight or nil [9]. Because of these mech-
anisms, oral S-1 administration generates a higher concentration of 5-FU
than a protracted intravenous infusion of 5-FU given in a dose equimolar
to the tegafur in S-1, whereas the incidence of adverse events concerning
the gastrointestinal tract does not increase. In a phase III trial of S-1 plus
carboplatin in the first-line setting of NSCLC, S-1 plus carboplatin was
not inferior to paclitaxel plus carboplatin in terms of the survival outcome.
S-1 showed activity in a second-line setting as well [10]. Of more interest,
single agent S-1 showed modest activity as a third-line or further-line treat-
ment [11,12]. On the other hand, capecitabine, which is another oral 5-
FU  agent,  showed  clinically  meaningful  results  in  NSCLC  when
combined with irinotecan and docetaxel in both first-line and second-line
settings [13-16].
Based on those findings, we conducted a phase II trial of S-1 containing
doublets, that is, S-1 plus either irinotecan or docetaxel, for patients who
had already received 3 lines of therapy or more, including at least a plat-
inum doublet and an EGFR TKI.
M ater ials  and  M eth od s
1. Eligibility
The eligible patients were diagnosed with histologically or cytologically
confirmed metastatic NSCLC. They had already received at least 3 lines
of treatment, including a platinum doublet and EGFR TKI therapy. The
other inclusion criteria were an age of 18 years and older, a Eastern Co-
operative Oncology Group (ECOG) performance status of 0 to 2, meas-
urable disease by the Response Evaluation Criteria in Solid Tumors
(RECIST) v1.0 and adequate bone marrow, renal, and hepatic function.
Patients with newly-diagnosed central nervous system metastases or any
unresolved chronic toxicity greater than National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (NCI CTCAE) grade (G)
2 from previous therapy were ineligible. All the patients provided written
informed consent before starting the study. The study was approved by
the Asan Medical Center Institutional Review Board (No.2006-0413) and
the study was performed in accordance with the Declaration of Helsinki
and the International Conference on Harmonisation/Good Clinical Prac-
tice.
2. Treatment
The treatment consisted of oral S-1 40 mg/m2 twice a day from D1
through D14 in combination of either irinotecan 150 mg/m2on D1 only
or docetaxel 35 mg/m2 on D1 and D8, and this was repeated every 3
weeks. The actual dose of S-1 was selected as follows: 40 mg twice a day
was given for a body surface area (BSA)＜1.25 m2, 50 mg twice a day
was given for a BSA of 1.25 m2but ＜1.5 m2and 60 mg twice a day was
given for a BSA≥1.5 m2. Prophylactic antiemetics, a 5-HT3 receptor an-
tagonist and 8 mg of dexamethasone were given 30 minutes before the
administration of irinotecan or docetaxel. However, further prophylactic
dexamethasone after docetaxel was not routinely administered in order
to reduce the risk of a hypersensitivity reaction. There was no concomitant
medication for S-1 either. The choice between the two treatments was
made at the treating physician’s discretion.
Before receiving treatment, each patient underwent a complete physical
examination, including laboratory tests, as well as a medical history eval-
uation, including documentation of concomitant medications and deter-
mining the performance status. Toxicities were graded using the CTCAE
v3.0. In addition, all the patients received chest radiographs and a chest
computed tomography scan that included the upper abdomen. Magnetic
resonance imaging of the brain and radionuclide bone scans were done if
needed.
Dose reductions and/or administration delays were planned in case of
severe hematological and/or non-hematological toxicities while on the
study’s treatment. Dose adjustments were made according to the system
showing the greatest degree of toxicity. Toxicities were graded using the
CTCAE v3.0. The doses of irinotecan or docetaxel and S-1 were adjusted
according to the degree of the hematologic and non-hematologic toxicity.
The dose was reduced by one dose level of irinotecan 25 mg/m2or doc-
etaxel 5 mg/m2and S-1 20 mg per day for the patients whose BSA was
≥1.25 mg and who had evidence of G4 hematologic toxicity or G3 or
more non-hematologic toxicity during any cycle of administration. If re-
covery from such toxicities was confirmed at a reduced dose, then ad-
ministration at the reduced dose was continued. If a patient with a BSA
＜1.25 m2or who was taking 40 mg twice a day experienced the above-
mentioned toxicities, then no further treatment with S-1 was done. If a
rest period of ＞4 weeks was required, then the patient was withdrawn
from the study. If reduction of more than two dose levels was required,
then the patient was withdrawn from the study.
3. Response assessment
The objective tumor response was assessed according to RECIST v1.0.
A complete response (CR) was defined as the disappearance of all lesions.
A partial response (PR) was defined as at least a 30% decrease in the sum
of the longest target lesion diameter, taking as a reference the longest base-
line diameter and/or the persistence of one or more non-target lesions. PD
was defined as at least a 20% increase in the sum of the longest diameter,
taking as a reference the smallest sum of the longest diameter recorded
after treatment or the appearance of one or more new lesions, or the un-Cancer Res Treat. 2011;43(4):212-216
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equivocal progression of existing non-target lesions. Stable disease (SD)
was defined as the absence of significant shrinkage or enlargement that
qualified as CR, PR or PD, taking as a reference the smallest sum of the
longest diameter recorded after treatment. The best tumor response of CR,
PR or SD should be confirmed and sustained for at least 6 weeks or longer.
The response was assessed every 2 cycles. Progression-free survival (PFS)
was defined as the interval between the date treatment started and the date
of documented disease progression or death from any cause. Overall sur-
vival was defined as the interval between the date treatment started and
the date of death from any cause. Patients lost to follow-up were censored
at the last date of contact.
4. Statistical considerations
This study was an open label, non-randomized, single-institution, sin-
gle-arm phase II study. The primary endpoint was the objective response
rate. A Simon mini-max two-stage design was chosen to determine the
total number of patients required for the phase II study. We set a response
rate of 30% as the target activity level and we chose 10% as the lowest
overall response rate of interest. The study was designed to have 80%
power to accept the hypothesis and 5% significance to reject the hypoth-
esis. For a total of 25 subjects, 15 were to be accrued during the first stage
and 10 were to be accrued during the second stage. If 1 or fewer responses
were observed during the first stage, then the study would stop early. If 5
or fewer responses were observed by the end of the study, then no further
investigation of the drug would be warranted. Allowing a loss to follow-
up rate of 10%, a total of 28 patients were required. The data was updated
as of June 30, 2011.
R esults
1. Patient characteristics
Between March 2007 and July 2009, 14 patients participated in the
study. Among them, 10 patients received irinotecan plus S-1 and the other
4 patients received docetaxel plus S-1. The characteristics of the patients
are listed in Table 1. As per protocol, all the patients received platinum-
based chemotherapy and EGFR TKI therapy.
2. Tumor responses in patients and survival
Out of the 14 patients there was no response, and only 2 showed SDs.
Therefore, we had to stop the study early as per protocol. With a median
follow-up time of 49 months, the median survival time was 5.6 months
(95% confidence interval [CI], 4.3 to 6.9 months) (Fig. 1). The median
PFS was 1.4 months (95% CI, 0 to 3.0 months).
3. Toxicity
There were 3 patients with G2 hematologic toxicity, 2 patients had G1
anemia, 1 patient had G3 neutropenia, and 1 patient had G2 neutropenia.
One patient experienced G3 diarrhea and 1 patient experienced G3 nau-
sea/vomiting. All the patients receiving S-1 and docetaxel manifested
alopecia. The other toxicities were G1/2 toxicities such as fatigue, mu-
cositis, etc., which were tolerable and manageable (Table 2).
Characteristic No. (n=14) %
Median age (range, yr) 59 (45-72)
Gender
Male 8 57.1
Female 6 42.9
ECOG performance status
18 57.1
2 6 42.9
Pathology
Squamous cell carcinoma 3 21.4
Adenocarcinoma 9 64.3
Non-small cell lung cancer, NOS 2 14.3
No. of prior chemotherapies including 
EGFR TKI therapy
3 10 71.4
43 21.4
51 7.1
ECOG, Eastern Cooperative Oncology Group; NOS, not ot-herwise
specified; EGFR TKI, epidermal growth factor receptor tyrosine ki-
nase inhibitor.
Table 1. Patient characteristics
Fig. 1. Survival outcomes.Dal Yong Kim, S-1 Doublets after Multiple Chemotherapies
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Discussion
Regrettably we did not observe the activity of a combination of S-1
and either irinotecan or docetaxel as a fourth-line or further-line therapy
in heavily-treated NSCLC patients. As per the protocol, we had to stop
the study early, which meant that we cannot recommend these regimens
for further investigation. In a retrospective study of a single S-1 agent in
a clinical setting, the authors reported that 5.7% of the enrolled patients
showed a PR and 34.2% had SD. Another retrospective study of peme-
trexed or docetaxel as third or fourth-line therapy also showed an objective
response rate of 15.4% [17]. But those studies might have inherent limi-
tations due to their retrospective nature. Our prospective study did not
confirm this kind of efficacy. The advances of treatment for NSCLC dur-
ing the last decade cause physicians to frequently see patients who have
PD after multiple chemotherapies, but they still have a good performance
status. As a result, they still have a chance to receive further cytotoxic
chemotherapy, when considering their performance status and the unused,
available chemotherapeutic agents. Actually, in our study, all the patients
had already received a platinum doublet and either gefitinib or erlotinib
or both, and most of them had also received either pemetrexed or doc-
etaxel. For such patients, many investigators, including us, have conducted
clinical trials of single or combination chemotherapy of cytotoxic agents
that have already showed their activity as first-line and second-line treat-
ments. They have also reported a few responses in phase II trials, but their
results hardly translated into success in the phase III trials. Like many
other studies, a rather unselected population participated in our study and
so a lower efficacy of the treatment could be expected, especially for heav-
ily-treated patients. We determined the response rate as the primary end-
point, and we would have chosen the PFS rate at some point instead of
the response rate as the primary endpoint. However, unlike targeted agents,
which are sometimes regarded as cytostatic drugs, most chemotherapeutic
agents are cytotoxic drugs, so the response rate might be better as the pri-
mary endpoint for cytotoxic agents than the progression-free rate [18].
On the other hand, we need to change the strategy of clinical trials in
this type of clinical setting. The most promising one might be to design
clinical trials based on the patients’ molecular characteristics, which are
usually discovered in other studies. For example, since information on
specific genotypes related to the pemetrexed-metabolizing genes, such as
SLC19A1, might be related to the clinical outcome, we can consider con-
ducting a clinical trial based on this genetic information [19]. Another
strategy should focus on many biomarkers such as epidermal growth fac-
tor receptor (EGFR) and KRASmutations, the copy number of cyclin D1,
the expression of vascular endothelial growth factor, or molecular driver
mutations such as the echinoderm microtubule-associated protein-like 4–
anaplastic lymphoma kinase (EML4-ALK) fusion gene or b-raf mutation.
We recommend that patients participate in clinical trials of newly-devel-
oped targeted agents for such targets [20,21].
C onclusion
Treatment with S-1 and either irinotecan or docetaxel did not yield ef-
ficacy in heavily-treated advanced NSCLC patients as fourth-line or fur-
ther-line therapy, and so this treatment cannot be recommended. 
C onflicts  of  Intere st
Conflict of interest relevant to this article was not reported.
Table 2. Toxicity profile
S-1 plus irinotecan (n=10) S-1 plus docetaxel (n=4)
Adverse event
G1 G2 G3 G4 G1 G2 G3 G4
Hematologic toxicity
Neutropenia 0 (0) 1 (10) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Anemia 2 (20) 3 (30) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Thrombocytopenia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Non-hematologic toxicity
Alopecia 0 (0) 0 (0) 0 (0) 0 (0) 3 (75) 1 (25) 0 (0) 0 (0)
Diarrhea 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue 0 (0) 3 (3) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0)
Nausea/Vomiting 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Elevated AST/ALT 0 (0) 0 (0) 0 (00) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Elevated bilirubin 1 (10) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Values are presented as number (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase.Cancer Res Treat. 2011;43(4):212-216
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